Can I get it?
Not for this use. Bremelanotide has no EU authorisation for it, so it cannot be prescribed or dispensed here for that purpose.
Why buying it online is risky
Bremelanotide · Klaipėda
Bremelanotide in Klaipėda: what you should know.
NOT AVAILABLE IN THE EUBremelanotide has no EU marketing authorisation for this use.
We don't prescribe it today, but our doctors can review your case and propose an equivalent sexual health treatment with EU approval and clinical evidence.
€35 one-offFull refund if a review is not approved
IN PLAIN TERMS
What Bremelanotide is, and how to get treatment
Bremelanotide, sold in the United States as Vyleesi, is an injection given under the skin of the stomach or thigh about 45 minutes before sex. It is for premenopausal women with persistently low sexual desire that causes them real distress, a diagnosis doctors call hypoactive sexual desire disorder. It works on desire signals in the brain, so it is nothing like the tablets men take for erection problems, and it is not meant to improve sexual performance. It is approved in the United States but has no marketing authorisation in the European Union, so no EU doctor can prescribe it and Hi-Doctor does not offer it. If low desire is troubling you, a GP or gynaecologist can look at hormones, mood, medication side effects and relationship factors together, which is the assessment this problem actually needs.
Bremelanotide has no EU marketing authorisation for this use. It may be an approved medicine for something else, or approved in another country — but not something a doctor here can prescribe for this.
Learn more about peptides at Peptidepedia.
What can I take instead?
Our doctors review every Sexual health option and recommend what fits your history and goals.
See all Sexual health optionsWhat do the studies show?
Every trial behind Bremelanotide is listed below with its registry number, how many people took part, and whether the results are peer-reviewed or a company announcement.
Jump to the studiesLocal consultation facts
Can I get Bremelanotide in Klaipėda?
Not through Hi-Doctor. Hi-Doctor does not prescribe Bremelanotide. People in Klaipėda, Lithuania, can request an online consultation for Sexual health with a licensed EU doctor, who may recommend an available option when clinically appropriate. If approved, the EU prescription arrives as a PDF for a pharmacist in Lithuania, who dispenses the locally marketed equivalent with the prescribed active ingredient.
Availability
Hi-Doctor does not prescribe Bremelanotide. The links below show options in Sexual health that our doctors can assess.
- Country
- Lithuania
- Language of service
- Spanish and English
- Prescription turnaround
- In less than 4 hours on average, only if the doctor approves
- Honoured locally
- PDF honoured locally for the prescribed active ingredient
How the EU prescription works where you are: In Lithuania, show the approved prescription PDF to a pharmacist. They honour it under EU cross-border rules and dispense the locally marketed equivalent with the prescribed active ingredient.
TREATMENT OPTIONS
Available treatment options
A licensed doctor decides case by case. We never prescribe without evaluation.
Rx · PDE5 inhibitor
Prescription only
Sildenafil (Viagra)
Phosphodiesterase-5 inhibitor. The doctor assesses it after ruling out cardiovascular contraindications.
Fast-acting tablets
€35 one-off
Rx · PDE5 inhibitor
Prescription only
Tadalafil 10/20mg
Long-acting PDE5 inhibitor. Available in low doses for daily use or higher doses on demand.
Tablets
€35 one-off
Rx · PDE5 inhibitor
Prescription only
Vardenafil 5/10/20mg
Alternative within the same class, sometimes better tolerated depending on the patient's profile.
Tablets
€35 one-off
Rx · PDE5 inhibitor
Prescription only
Avanafil 50/100/200mg
Faster-acting PDE5 inhibitor. An option for selected patients based on medical judgement.
Tablets
€35 one-off
Rx · topical cream
Prescription only
Alprostadil (Vitaros)
Topical option for patients who don't respond to PDE5 inhibitors or have contraindications. The doctor assesses suitability.
Topical cream
€35 one-off
You pay for any medication separately at the pharmacy you choose. Hi-Doctor does not sell medications.
WHAT IT COSTS
One plan, reviewed by a doctor.
Sexual health
ONE-OFF
€35 one-off
One consultation, one doctor, one decision.
Nothing stored publicly, ever
Start consultation
Full refund if a review is not approved
WHAT'S INCLUDED
- Consultation reviewed by an EU-licensed doctor
- Electronic prescription if approved
- Full refund if not approved
Full refund if a review is not approved
If a review is not approved, we refund the €35 consultation fee in full.
Note: The medication, if the doctor prescribes it, is paid separately at the pharmacy at the price it sets. Hi-Doctor does not sell medications.
VERIFIED EVIDENCE
Bremelanotide: evidence and regulatory guide.
WHAT IT IS
How it works
Bremelanotide is a melanocortin receptor agonist: it acts on signalling pathways in the brain that are involved in sexual desire, rather than on blood flow to the genitals.
- MC1R
- MC4R
DEVELOPMENT STAGE
Not marketed in the EU
Trial register2 registered trials
Every NCT identifier links to its ClinicalTrials.gov record. A readout is not the same as peer-reviewed publication.
| TRIAL / NCT | POPULATION | PARTICIPANTS | STATUS | READOUT / COMPLETION |
|---|---|---|---|---|
| RECONNECT study 301NCT02333071 | Premenopausal women with acquired, generalised hypoactive sexual desire disorder, at US and Canadian sites | 723 | Read out | 2016-07-26 |
| RECONNECT study 302NCT02338960 | Premenopausal women with acquired, generalised hypoactive sexual desire disorder, at US and Canadian sites | 714 | Read out | 2016-08-04 |
What the studies reported
Results are grouped by source and evidence grade so journal data and manufacturer announcements cannot be confused.
Peer-reviewed
Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol 2019;134(5):899-908. doi:10.1097/AOG.0000000000003500 (PMID 31599840)| DOSE OR GROUP | MEAN WEIGHT CHANGE | WEEKS |
|---|---|---|
| 1.75 mg injected as needed (study 301) | Female Sexual Function Index desire domain +0.30 vs placebo (P<.001); Female Sexual Distress Scale item 13 −0.37 vs placebo (P<.001) | 24 |
| 1.75 mg injected as needed (study 302) | Female Sexual Function Index desire domain +0.42 vs placebo (P<.001); Female Sexual Distress Scale item 13 −0.29 vs placebo (P=.005) | 24 |
| 1.75 mg injected as needed (both studies combined) | Female Sexual Function Index desire domain +0.35 vs placebo (P<.001); Female Sexual Distress Scale item 13 −0.33 vs placebo (P<.001) | 24 |
Of the 1,267 women randomised, 96.6% were recruited at US sites and 85.6% were white, and the differences from placebo are small movements on questionnaire scales whose day-to-day meaning is debated.
Sources
Last reviewed 2026-07-27
- US FDA prescribing information — VYLEESI (bremelanotide) injection, via DailyMed
- US FDA approved label PDF — VYLEESI (bremelanotide), 2019
- Kingsberg et al., Obstet Gynecol 2019 — RECONNECT phase 3 trials
- EMA public medicines register (checked 27 July 2026 — no entry for bremelanotide or Vyleesi as an authorised, refused or withdrawn application)
- ClinicalTrials.gov · NCT02333071
- ClinicalTrials.gov · NCT02338960
NAMED SAFETY SIGNALS
What has been reported with Bremelanotide.
Nausea
Reported by 40.0% of women given bremelanotide versus 1.3% on placebo in the phase 3 trials.
Flushing
Reported by 20.3% of women given bremelanotide versus 0.3% on placebo.
Injection site reactions
Reported by 13.2% of women given bremelanotide versus 8.4% on placebo.
Headache
Reported by 11.3% of women given bremelanotide versus 1.9% on placebo.
Stopping treatment because of side effects
18% of women on bremelanotide stopped the studies because of adverse reactions, versus 2% on placebo.
Temporary blood pressure rise
Each dose caused maximum increases of about 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after injection, with heart rate falling by up to 5 beats per minute; the US label contraindicates it in uncontrolled high blood pressure or known cardiovascular disease.
Darkened patches of skin
Focal hyperpigmentation was reported in 1% of patients receiving up to 8 monthly doses, and in 38% of those given a dose daily for 8 days.
UNAPPROVED PRODUCTS ONLINE
Why buying Bremelanotide online is not a shortcut.
No doctor in the EU can prescribe it for this use — including ours. It may be authorised in another country, or for a different condition.
Check the EU common logo
A legitimate online pharmacy in the EU must display the common logo linked to its national register. The logo is a verification check; it cannot make an unapproved medicine legal.
How the EU common logo worksFREQUENTLY ASKED QUESTIONS
Questions about Bremelanotide.
OTHER SEXUAL HEALTH TREATMENTS